When.com Web Search

  1. Ads

    related to: fda approved medications for osteoporosis

Search results

  1. Results From The WOW.Com Content Network
  2. Romosozumab - Wikipedia

    en.wikipedia.org/wiki/Romosozumab

    Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in Japan, the United States and the European Union in 2019. [7] [10] [11] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [12]

  3. Strontium ranelate - Wikipedia

    en.wikipedia.org/wiki/Strontium_ranelate

    Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. [1] The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by ...

  4. Zoledronic acid - Wikipedia

    en.wikipedia.org/wiki/Zoledronic_acid

    Zoledronic acid, also known as zoledronate and sold under the brand name Zometa among others, [7] by Novartis among others, is a medication used to treat a number of bone diseases. [3] These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget's disease of bone [3] and Duchenne muscular dystrophy (DMD).

  5. Top aging expert says these 4 FDA-approved drugs hold promise ...

    www.aol.com/finance/global-aging-doctor-says-4...

    Bisphosphonates, scoring 11 out of 12, treat osteoporosis, which affects 10 million Americans. They are prescribed to those with the condition to reduce the loss of bone density.

  6. Does Medicare cover Forteo, and how much does it cost? - AOL

    www.aol.com/does-medicare-cover-forteo-much...

    Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth.

  7. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]